Autonomix Medical to Present Final Analysis on Pain Mitigation in Pancreatic Cancer at SIO 2026 Annual Scientific Meeting
Autonomix Medical, Inc. (AMIX)
Company Research
Source: GlobeNewswire
THE WOODLANDS, TX, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that final clinical data evaluating its transvascular radiofrequency (RF) ablation approach for pain mitigation in pancreatic adenocarcinoma will be presented at the Society of Interventional Oncology (SIO) 2026 Annual Scientific Meeting happening February 4-8, 2026 in Savannah, GA. The presentation, titled “Pain Mitigation in Pancreatic Adenocarcinoma: A Final Analysis of Neurolysis via Transvascular Radiofrequency (RF) Ablation,” has been accepted as an ePoster presentation for the conference’s Science and Sips Reception, highlighting emerging innovations in interventional oncology. The ePoster (Abstract #327) will be presented by Clarke Wilkirson, PhD on Friday, February 6, 2026, from 5:30 PM to 6:30 PM EST, in the ePoster corridor outside the exhibit hall.
Show less
Read more
Impact Snapshot
Event Time:
AMIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMIX alerts
High impacting Autonomix Medical, Inc. news events
Weekly update
A roundup of the hottest topics
AMIX
News
- Autonomix Medical (NASDAQ:AMIX) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Autonomix Showcases Compelling PoC Study Clinical Data Showing Rapid and Durable Pain Relief Across All Disease Stages of Pancreatic Cancer at the 2026 ASCO Gastrointestinal (GI) Cancers SymposiumGlobeNewswire
- Autonomix Medical, Inc. Granted European Patent on Platform Technology Enabling Precision Nerve-Targeted Therapies in Cardiology [Yahoo! Finance]Yahoo! Finance
- Autonomix Medical, Inc. Granted European Patent on Platform Technology Enabling Precision Nerve-Targeted Therapies in CardiologyGlobeNewswire
- Autonomix Medical, Inc. (NASDAQ: AMIX) Highlights Expanding IP Portfolio and Multi-Indication Platform Strategy in Virtual Investor CEO Connect Segment [Yahoo! Finance]Yahoo! Finance
AMIX
Sec Filings
- 1/16/26 - Form 8-K
- 1/9/26 - Form 8-K
- 12/12/25 - Form 424B3
- AMIX's page on the SEC website